Bupivacaine/Meloxicam

布比卡因/美洛昔康

Report date: 2025/09/26 16:39:25

Base Information

Drug NameBupivacaine/Meloxicam
Drug Alias Name布比卡因美洛昔康Meloxicam and BupivacaineMeloxicam/Bupivacaine美洛昔康/布比卡因美洛昔康布比卡因 +[11
ClassificationSmall molecules
Mechanisms of ActionCyclooxygenase-2 inhibitorsCyclooxygenase-1 inhibitors
TargetsSodium channel alpha subunitCyclooxygenase-2Cyclooxygenase-1
Therapy Area/IndicationsSurgical WoundPain, PostoperativeVulvodynia +[6
Global Approved IndicationsPain, Postoperative
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2020/09/24
Country/TerritoryBelgiumUnited StatesEU
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesHeron Therapeutics
China Registration ClassN/A

Develop Information

Active IndicationsSurgical WoundPain, PostoperativeVulvodynia +[5
Inactive IndicationsBunion

Other Information

ATC CodeM01AC56N01BB51
Related LinksN/A